STARKAP Protocol: preliminary assessment of safety and tolerability of dostarlimab in combination antiretroviral therapy (cART)-refractory HIV associated Kaposi’s Sarcoma

STARKAP Protocol: preliminary assessment of safety and tolerability of dostarlimab in combination antiretroviral therapy (cART)-refractory HIV associated Kaposi’s Sarcoma

Abstract Background Kaposi sarcoma (KS) is a mesenchymal malignancy induced by human herpes virus-8 (HHV-8). Whilst combined anti-retroviral therapy (cART) has substantially reduced the incidence of KS in people living with HIV (PLWH), KS remains the commonest neoplasia in this population. In up to...

Full description

Saved in:
Bibliographic Details
Main Authors: Claudia A. M. Fulgenzi, Alessia Dalla Pria, Alberto Giovanni Leone, Maria Martinez, Elena Ferrer Martinez Del Peral, Maria Eleanor Flores, Mark Bower, David J. Pinato
Format: Article
Language:English
Published: BMC 2025-07-01
Series:BMC Cancer
Subjects:
Kaposi's sarcoma
Immunotherapy
HIV
Online Access:https://doi.org/10.1186/s12885-025-14326-2
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12885-025-14326-2

Similar Items